| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S15842 R65216 |
Bromley (Levetiracetam) (Controls exposed to LTG), 2023 | Preterm birth (gestational age < 37 weeks) | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.67 [0.26;1.75] C excluded (control group) |
7/70 15/106 | 22 | 70 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S15843 R65229 |
Bromley (Levetiracetam) (Controls unexposed, sick), 2023 | Preterm birth (gestational age < 37 weeks) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No | 0.70 [0.25;1.91] C | 7/70 11/80 | 18 | 70 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12619 R47573 |
Van Marter (Levetiracetam) (Controls unexposed, disease free), 2021 | Premature (≤36 wk) | at least 1st trimester | prospective cohort | unexposed, disease free excluded | Adjustment: No |
1.10 [0.46;2.68] C excluded (control group) |
11/97 11/106 | 22 | 97 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12616 R47555 |
Van Marter (Levetiracetam) (Controls unexposed, sick), 2021 | Premature (≤36 wk) | at least 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 1.79 [0.21;14.97] C | 11/97 1/15 | 12 | 97 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8083 R24688 |
Aydin (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2020 | Preterm delivery (before 37 weeks of gestation) | throughout pregnancy | retrospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
0.68 [0.01;39.07] C excluded (control group) |
0/10 0/7 | 0 | 10 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8081 R24668 |
Aydin (Levetiracetam) (Controls unexposed, sick), 2020 | Preterm delivery (before 37 weeks of gestation) | throughout pregnancy | retrospective cohort | unexposed, sick | Adjustment: No | 0.41 [0.02;9.43] C | 0/10 2/22 | 2 | 10 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S10072 R36661 |
Coste (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2020 | Gestational age at birth (< 37 WA) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No |
1.35 [0.96;1.89] C excluded (control group) |
51/621 131/2,108 | 182 | 621 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7807 R23109 |
Coste (Levetiracetam) (Controls unexposed, NOS), 2020 | Gestational age at birth (< 37 WA) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: No | 1.59 [1.19;2.11] C | 51/621 91,255/1,710,441 | 91,306 | 621 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S301 R16636 |
Arkilo (Levetiracetam), 2015 | Premature delivery | during pregnancy (anytime or not specified) | retrospective cohort | exposed to other treatment, sick | Adjustment: No | 1.56 [0.22;10.96] C | 2/11 3/24 | 5 | 11 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5932 R15143 |
Artama (Levetiracetam) (Controls exposed to Lamotrigine, sick), 2013 | Preterm birth (<37 gestational weeks) | during pregnancy (anytime or not specified) | population based cohort retrospective | exposed to other treatment, sick excluded | Adjustment: No |
3.75 [0.71;19.83] C excluded (control group) |
2/13 8/173 | 10 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5913 R14934 |
Artama (Levetiracetam) (Controls unexposed, disease free), 2013 | Preterm birth (<37 gestational weeks) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, disease free excluded | Adjustment: Yes |
3.54 [0.77;16.36] excluded (control group) |
2/13 30,027/719,509 | 30,029 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S5921 R15030 |
Artama (Levetiracetam) (Controls unexposed, sick), 2013 | Preterm birth (<37 gestational weeks) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: Yes | 3.33 [0.67;16.56] | 2/13 85/1,793 | 87 | 13 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 6 studies | 1.52 [1.16;1.98] | 91,430 | 822 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Levetiracetam) (Controls unexposed, sick; 2: Levetiracetam) (Controls unexposed, sick; 3: Levetiracetam) (Controls unexposed, sick; 4: Levetiracetam) (Controls unexposed, NOS; 5: Levetiracetam; 6: Levetiracetam) (Controls unexposed, sick;
Asymetry test p-value = 0.6314 (by Egger's regression)
slope=0.4830 (0.1829); intercept=-0.2854 (0.5503); t=0.5186; p=0.6314
excluded 5932, 5913, 8083, 10072, 12619, 15842